Faeth Therapeutics (FTH) Shares Outstanding (2020 - 2026)
Faeth Therapeutics' (FTH) quarterly Shares Outstanding (Entity) came in at $1.3 million in Q1 2026, down 94.68% YoY from $25.2 million in Q1 2025, and up 6.23% on a QoQ basis from $1.3 million in Q4 2025.
Faeth Therapeutics (FTH) Shares Outstanding (2020 - 2026) Analysis & Trends
Faeth Therapeutics (FTH) has 7 years of Shares Outstanding (Entity) data on file, last reported at $1.3 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) fell 94.68% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 94.68% YoY) and the FY2025 annual result came in at $1.3 million, down 94.99% from the prior year.
- Shares Outstanding (Entity) grew to $1.3 million in Q1 2026, from $1.3 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $31.0 million in Q1 2023 to a low of $1.3 million in Q2 2025.
- A 5-year average of $21.3 million and a median of $25.2 million in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) jumped 62.3% — and 2025, when it slumped 94.99%.
- Tracing FTH's Shares Outstanding (Entity) over 5 years: stood at $30.8 million in 2022, then retreated by 18.64% to $25.0 million in 2023, then grew by 0.6% to $25.2 million in 2024, then tumbled by 94.99% to $1.3 million in 2025, then gained by 6.23% to $1.3 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $1.3 million (Q1 2026), $1.3 million (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 445.06 Mn |
| 10 | Faeth Therapeutics | 179.79 Mn | 179.79 Mn | - | 5.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.64 Mn |
| Mar 31, 2026 | 1.30 Mn |
| Dec 31, 2025 | 1.26 Mn |
| Sep 30, 2025 | 1.26 Mn |
| Jun 30, 2025 | 1.26 Mn |
| Mar 31, 2025 | 25.19 Mn |
| Dec 31, 2024 | 25.12 Mn |
| Sep 30, 2024 | 25.15 Mn |
| Jun 30, 2024 | 25.10 Mn |
| Mar 31, 2024 | 25.05 Mn |
| Dec 31, 2023 | 27.95 Mn |
| Sep 30, 2023 | 25.51 Mn |
| Jun 30, 2023 | 30.51 Mn |
| Mar 31, 2023 | 30.87 Mn |
| Dec 31, 2022 | 30.70 Mn |
| Sep 30, 2022 | 30.72 Mn |
| Jun 30, 2022 | 30.70 Mn |
| Mar 31, 2022 | 30.65 Mn |
| Dec 31, 2021 | 27.71 Mn |
| Sep 30, 2021 | 30.59 Mn |